KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $28.9 million.

  • Rigel Pharmaceuticals' Non-Current Assets fell 16.22% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 16.22%. This contributed to the annual value of $28.9 million for FY2024, which is 60.77% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Non-Current Assets stood at $28.9 million for FY2024, which was up 60.77% from $18.0 million recorded in FY2023.
  • Rigel Pharmaceuticals' Non-Current Assets' 5-year high stood at $28.9 million during FY2024, with a 5-year trough of $12.9 million in FY2021.
  • Its 3-year average for Non-Current Assets is $21.7 million, with a median of $18.4 million in 2022.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 39.89% in 2021, then spiked by 60.77% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Non-Current Assets stood at $21.4 million in 2020, then slumped by 39.89% to $12.9 million in 2021, then surged by 42.88% to $18.4 million in 2022, then declined by 2.27% to $18.0 million in 2023, then skyrocketed by 60.77% to $28.9 million in 2024.